Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

Cancer Cell International
Xinmiao YangZhenzhou Shen

Abstract

Suberoyl bis-hydroxamic acid (SBHA) is a histone deacetylase (HDAC) inhibitor and exerts anti-growth effects in several malignancies including breast cancer. Proteasome inhibitors such as Bortezomib and MG-132 constitute novel anticancer agents. In this study, we investigated the synergistic antitumour activity of SBHA in combination with proteasome inhibitors. MCF-7 and MDA-MB-231 breast cancer cells were treated with SBHA, Bortezomib, and MG-132 alone or in combination for 72 h. Cell proliferation, colony formation, apoptosis and gene expression changes were examined. SBHA, Bortezomib, and MG-132 alone significantly inhibited the proliferation and colony formation and induced apoptosis in MCF-7 and MDA-MB-231 cells. Combined treatment showed a good synergistic antitumour effect against breast cancer cells. The p53 protein level was significantly elevated by combined treatment with SBHA and proteasome inhibitors. Moreover, combined treatment increased the expression of Bax, Bcl-xS, and Bak and decreased the expression of Bcl-2. Combination of SBHA with proteasome inhibitors causes synergistic anticancer effects on breast cancer cells. The potential molecular mechanism may involve induction of p53 and modulation of the Bcl-2 fa...Continue Reading

References

Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Liang ZhaoJessie L-S Au
Apr 30, 2005·Cell Death and Differentiation·L LindenboimR Stein
Mar 21, 2006·Molecular Cancer Therapeutics·Jordi Codony-ServatJoan Albanell
Sep 19, 2006·Briefings in Functional Genomics & Proteomics·Hiroki FukudaMasami Horikoshi
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nika N Danial
Apr 15, 2008·Future Oncology·K Stephen Suh, Andre Goy
Nov 26, 2008·Acta Pharmacologica Sinica·Zhi-gang ZhuangWei Jin
Jun 25, 2009·Nature Reviews. Cancer·Thomas G Cotter
Jul 15, 2009·Biochemical and Biophysical Research Communications·Sylwia FlisJacek Spławiński
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram
Feb 19, 2010·The Cancer Journal·Steven J Isakoff
Jul 24, 2010·Molecular and Cellular Biochemistry·Bo Ra You, Woo Hyun Park
Dec 29, 2010·Journal of Biomedicine & Biotechnology·Mario Federico, Luigi Bagella
Apr 6, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Azmi YerlikayaEngin Ulukaya
Nov 16, 2012·Current Pharmaceutical Design·Tiffany Devine, Mu-Shui Dai
May 3, 2013·The Journal of Clinical Investigation·Shruti BhattJuan Carlos Ramos
Jan 5, 2014·Molecular and Cellular Biochemistry·Rafał KrętowskiMarzanna Cechowska-Pasko
Feb 15, 2014·Cell Cycle·Jason M BecktaKristoffer Valerie
Mar 13, 2014·International Journal of Molecular Sciences·Li-Xia FengNa Zhang
May 24, 2014·Genetics and Molecular Research : GMR·I KilicciogluC Yucel Bilen

❮ Previous
Next ❯

Citations

Jun 2, 2018·Current Medicinal Chemistry·Faria SultanaAhmed Kamal
Aug 23, 2016·International Journal of Molecular Sciences·Xi-Feng ZhangSangiliyandi Gurunathan

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
electrophoresis
flow cytometry

Software Mentioned

CellQuest
Scion Image Beta

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

© 2022 Meta ULC. All rights reserved